comparemela.com
Home
Live Updates
Triple Therapy for Squamous NSCLC Shows Real-World Clinical Benefit : comparemela.com
Triple Therapy for Squamous NSCLC Shows Real-World Clinical Benefit
Sintilimab immunotherapy is not only effective when combined with gemcitabine and chemotherapy, but it may be a novel option when added to paclitaxel/nab-paclitaxel in squamous non–small cell lung cancer.
Related Keywords
Guangzhou
,
Guangdong
,
China
,
,
Research Project Of City
,
Zhongnanshan Medical Foundation Of Guangdong Province
,
School Institute Joint Funding
,
Key Laboratory Of Respiratory
,
Technology Bureau
,
State Key Laboratory
,
Respiratory Disease The Open Project
,
Applied Fundamental Research Project
,
Joint Funding Project
,
Guangzhou Science
,
Zhongnanshan Medical Foundation
,
Lung Cancer
,
Ung Carcinoma
,
Ancer Lung
,
Non Small Cell Lung Cancer
,
Nsclc
,
Chemotherapy
,
Neoplasm
,
Tumor
,
Biologic Therapy
,
Immunotherapy
,
Peer Review
,
comparemela.com © 2020. All Rights Reserved.